Regulus Therapeutics

Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. The Company's Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease. It has a research collaboration with Biogen focused on the discovery of microRNAs as biomarkers for multiple sclerosis and has completed research for another pharmaceutical company to explore microRNAs as biomarkers for specific patient populations. The Company is developing RG-101, an N-Acetylgalactosamine (GalNAc)-conjugated anti-miR targeting miR-122; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, and RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107.

Type
Public
HQ
San Diego, US
Founded
2007
Size (employees)
97 (est)+2%
Regulus Therapeutics was founded in 2007 and is headquartered in San Diego, US

Key People at Regulus Therapeutics

David Baltimore

David Baltimore

Director

Regulus Therapeutics Office Locations

Regulus Therapeutics has an office in San Diego
San Diego, US (HQ)
10614 Science Center Dr

Regulus Therapeutics Metrics

Regulus Therapeutics Financial Metrics

Revenue (2016)

$1.2 m

Revenue growth (2015-16), %

(94%)

Net income (2016)

($81.8 m)

Market capitalization (21-Mar-2017)

$62.2 m

Closing share price (21-Mar-2017)

$1.2

Cash (31-Dec-2016)

$14.9 m
Regulus Therapeutics's current market capitalization is $62.2 m.
Regulus Therapeutics's revenue was reported to be $1.2 m in FY, 2016 which is a 94.2% decrease from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

$19.6 m$7.7 m$20.8 m$1.2 m

Revenue growth, %

(61%)171%(94%)

Net Income

($18.7 m)($56.7 m)($55.7 m)($81.8 m)
FY, 2013FY, 2014FY, 2015FY, 2016

Cash

$17.8 m$37.3 m$16 m$14.9 m

Accounts Receivable

Inventories

$4.2 m

Current Assets

$117.2 m$165 m$134.3 m$87.5 m

PP&E

$3.8 m$3.6 m$5.4 m$11.8 m

Total Assets

$123.1 m$171.5 m$141.1 m$100.7 m

Accounts Payable

$1.2 m$2.2 m$2.7 m$5.8 m

Current Liabilities

$10.4 m$35.2 m$12.6 m$13.8 m

Additional Paid-in Capital

$172.5 m$267.9 m$315.7 m$329.5 m

Retained Earnings

($79.1 m)($135.8 m)($191.5 m)($273.4 m)

Total Equity

$93.5 m$132 m$124.1 m$56.1 m

Financial Leverage

1.3 x1.3 x1.1 x1.8 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

($18.7 m)($56.7 m)($55.7 m)($81.8 m)

Depreciation and Amortization

$1.4 m$1.5 m$1.6 m$2.3 m

Accounts Receivable

Inventories

Accounts Payable

$860 k$940 k$529 k$3.1 m

Cash From Operating Activities

($28.3 m)($39.5 m)($49.9 m)($56.9 m)

Purchases of PP&E

($800 k)($1.1 m)($1.4 m)($913 k)

Cash From Investing Activities

($40.9 m)($29.2 m)$21.5 m$35.3 m

Interest Paid

$37 k$39 k($27 k)($981 k)

Income Taxes Paid

$1 k$1 k($1 k)($1 k)

Regulus Therapeutics Market Value History

Regulus Therapeutics Online Presence

Regulus Therapeutics News

Regulus Therapeutics Company Life

You may also be interested in